direct-to-consumer genetic test
Smarter science, sharper strategy: Expert insights from ASCO® 2026
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Patients are telling the truth — just not to you
Patients are often most honest outside the clinic—revealing vital insights that can help clinical trial teams build trust, improve participation and collect better data.
NEW PHARMA-EXCLUSIVE WEBINAR: Beyond the Hype; Practical, Compliant AI Solutions for Pharma Engagement
See how top-tier pharma teams use compliant AI tools and virtual QIPs to capture real-time market intelligence, confidence scores, and audience insights from live dashboards
Permission to pause: making treatment breaks part of the cancer care conversation
Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.
Key takeaways from ASCO® 2026
Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year's congress revealed for pharmaceutical organisations. Together, they...
Real Chemistry Launches Real Chemistry ANATOMI, an AI Ecosystem Purpose-Built for Healthcare Commercialization
The unique combination of technology marks 25 years of industry innovation and expertise, and signals company’s next phase of business growth and client value
Webcast | Smarter science, sharper strategy: Expert perspectives from ASCO® 2026
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Pfizer and Innovent Biologics agree on deal worth up to $10.5bn
The companies plan to research and develop 12 new cancer treatments
The silent drop-off: How disengagement shows up in everyday behaviour
In healthcare, disengagement rarely announces itself. It doesn’t always appear as refusal or a clear decision to stop treatment. More often, it shows up quietly, in what is delayed, avoided...
One-carbon Therapeutics collaborates with Tempus in cancer treatment
The treatment is currently being evaluated in a phase 1/2 multicentre clinical study
Gilead to acquire Tubulis for up to $5bn
The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need
HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category
Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....